Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
TLSI
$5.32
$
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
Next Earnings
2026-02-25
Beta
0.421
Average Volume
Market Cap
Last Dividend
CIK
0001826667
ISIN
US89680M1018
CUSIP
89680M101
CEO
Mary T. Szela
Sector
Healthcare
Industry
Medical - Devices
Full Time Employees
110
IPO Date
2021-02-08
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Market Today: Tariffs, AI Jitters; LLY, MRK, WBD in Focus | Guru Stock PicksBernard Horn has made the following transactions:Reduce in XSWX: BARN by 39.89%Sold out in CGAdd in TSN by 18.45%New position in HKSE:01299Stock | GuruFocus | 2026-02-23 17:39:00 |
| TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering | WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced it has priced its previously announced underwritten public offering of 9,756,100 shares of its common stock at a public offering price of $4.10 per share. All of the shares in the offering are. | Business Wire | 2026-02-20 08:00:00 |
| TriSalus Life Sciences Proposes Public Offering | WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering are to be sold by TriSalus. In addition, TriSalus i. | Business Wire | 2026-02-19 16:01:00 |
| TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors | WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology-focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced changes to its Board of Directors. TriSalus announced that Dr. Arjun “JJ” Desai, a member of the Board since August of 2023, has elected to resign from the Board. The Company and the Board exp. | Business Wire | 2026-02-09 09:00:00 |
| TriSalus Life Sciences, Inc. (TLSI) Upgraded to Buy: Here's What You Should Know | TriSalus Life Sciences, Inc. (TLSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). | Zacks Investment Research | 2026-01-14 13:01:10 |
| TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance | WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The Company anticipates fourth quarter 2025 revenues of approximately $13.2 million and ful. | Business Wire | 2026-01-12 07:00:00 |
| Terumo (OTCMKTS:TRUMY) vs. TriSalus Life Sciences (NASDAQ:TLSI) Critical Survey | TriSalus Life Sciences (NASDAQ: TLSI - Get Free Report) and Terumo (OTCMKTS:TRUMY - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation. Analyst Ratings This is a breakdown of recent | Defense World | 2025-12-30 02:08:47 |
| Contrasting Stagezero Life Sciences (OTCMKTS:SZLSF) and TriSalus Life Sciences (NASDAQ:TLSI) | Stagezero Life Sciences (OTCMKTS:SZLSF - Get Free Report) and TriSalus Life Sciences (NASDAQ: TLSI - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings. Valuation and Earnings This table | Defense World | 2025-12-30 01:48:54 |
| TriSalus Life Sciences, Inc. (TLSI) Discusses Innovative Approaches for Thyroid Artery Embolization and Tumor-Targeted Therapies Transcript | TriSalus Life Sciences, Inc. (TLSI) Discusses Innovative Approaches for Thyroid Artery Embolization and Tumor-Targeted Therapies Transcript | Seeking Alpha | 2025-12-15 17:59:33 |
| AWM Investment Company Inc. Acquires New Shares in TriSalus Life Sciences, Inc. $TLSI | AWM Investment Company Inc. bought a new stake in shares of TriSalus Life Sciences, Inc. (NASDAQ: TLSI) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,250,000 shares of the company's stock, valued at approximately $6,812,000. AWM Investment | Defense World | 2025-12-13 03:51:02 |
| TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025 | WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Monday, December 15, 2025 at 2:00 PM ET featuring Juan C. Camacho, MD (Florida State University), who will join company management to discuss the unmet need and cur. | Business Wire | 2025-12-04 16:01:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| 424B5 | 2026-02-20 | 2026-02-20 | View Filing |
| 8-K | 2026-02-20 | 2026-02-20 | View Filing |
| 424B5 | 2026-02-19 | 2026-02-19 | View Filing |
| 4 | 2026-02-11 | 2026-02-11 | View Filing |
| 3 | 2026-02-11 | 2026-02-11 | View Filing |
| 8-K | 2026-02-09 | 2026-02-09 | View Filing |
| 8-K | 2026-01-12 | 2026-01-12 | View Filing |
| EFFECT | 2025-12-04 | 2025-12-05 | View Filing |
| 4 | 2025-11-25 | 2025-11-25 | View Filing |
| 4 | 2025-11-25 | 2025-11-25 | View Filing |
| 4 | 2025-11-25 | 2025-11-25 | View Filing |
| 4 | 2025-11-25 | 2025-11-25 | View Filing |
| 4 | 2025-11-25 | 2025-11-25 | View Filing |
| 4 | 2025-11-25 | 2025-11-25 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| S-3 | 2025-11-13 | 2025-11-13 | View Filing |
| 10-Q | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-13 | 2025-11-13 | View Filing |
| SC 13G | 2025-11-03 | 2025-11-03 | View Filing |
| 8-K | 2025-10-01 | 2025-10-01 | View Filing |
| 4 | 2025-08-29 | 2025-08-29 | View Filing |
| 8-K | 2025-08-29 | 2025-08-29 | View Filing |
| SC 13G | 2025-08-18 | 2025-08-18 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| SC 13G | 2025-08-14 | 2025-08-14 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| SC 13D/A | 2025-08-04 | 2025-08-04 | View Filing |
| SC 13D/A | 2025-08-01 | 2025-08-01 | View Filing |
| SC TO-I/A | 2025-07-25 | 2025-07-25 | View Filing |
| 8-K | 2025-07-24 | 2025-07-24 | View Filing |
| EFFECT | 2025-07-23 | 2025-07-23 | View Filing |
| SC TO-I/A | 2025-07-15 | 2025-07-15 | View Filing |
| S-4/A | 2025-07-11 | 2025-07-11 | View Filing |
| 3 | 2025-07-10 | 2025-07-10 | View Filing |
| 4 | 2025-06-27 | 2025-06-27 | View Filing |
| 4 | 2025-06-27 | 2025-06-27 | View Filing |
| 4 | 2025-06-27 | 2025-06-27 | View Filing |
| 4 | 2025-06-27 | 2025-06-27 | View Filing |
| 4 | 2025-06-27 | 2025-06-27 | View Filing |
| 4 | 2025-06-27 | 2025-06-27 | View Filing |
| 4 | 2025-06-27 | 2025-06-27 | View Filing |
| 8-K | 2025-06-23 | 2025-06-23 | View Filing |
| S-4 | 2025-06-23 | 2025-06-23 | View Filing |
| SC TO-I | 2025-06-23 | 2025-06-23 | View Filing |
| 8-K | 2025-06-16 | 2025-06-16 | View Filing |
| EFFECT | 2025-06-12 | 2025-06-12 | View Filing |
| EFFECT | 2025-06-02 | 2025-06-02 | View Filing |
| S-3 | 2025-05-30 | 2025-05-30 | View Filing |
| 8-K | 2025-05-30 | 2025-05-30 | View Filing |
| 10-K/A | 2025-05-30 | 2025-05-30 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 10-Q | 2025-05-15 | 2025-05-15 | View Filing |
| 8-K | 2025-05-15 | 2025-05-15 | View Filing |
| D | 2025-05-08 | 2025-05-08 | View Filing |
| EFFECT | 2025-05-05 | 2025-05-05 | View Filing |
| SC 13D/A | 2025-05-02 | 2025-05-02 | View Filing |
| ARS | 2025-04-30 | 2025-04-30 | View Filing |
| DEF 14A | 2025-04-30 | 2025-04-30 | View Filing |
| 425 | 2025-04-30 | 2025-04-30 | View Filing |
| 8-K | 2025-04-30 | 2025-04-30 | View Filing |
| S-3 | 2025-04-28 | 2025-04-28 | View Filing |
| S-8 | 2025-04-25 | 2025-04-25 | View Filing |
| S-3 | 2025-04-25 | 2025-04-25 | View Filing |
| 8-K | 2025-04-23 | 2025-04-23 | View Filing |
| 8-K | 2025-04-17 | 2025-04-17 | View Filing |
| 10-K | 2025-04-15 | 2025-04-15 | View Filing |
| NT 10-K | 2025-03-28 | 2025-03-28 | View Filing |
| 8-K | 2025-03-27 | 2025-03-27 | View Filing |
| 8-K | 2025-02-25 | 2025-02-25 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 8-K | 2025-02-19 | 2025-02-18 | View Filing |
| 4 | 2025-02-11 | 2025-02-11 | View Filing |
| 4 | 2025-02-11 | 2025-02-11 | View Filing |
| 4 | 2025-02-11 | 2025-02-11 | View Filing |
| 4 | 2025-02-06 | 2025-02-06 | View Filing |
| 8-K | 2025-02-03 | 2025-02-03 | View Filing |
| 4 | 2025-01-31 | 2025-01-31 | View Filing |
| 3 | 2025-01-31 | 2025-01-31 | View Filing |
| 4 | 2025-01-31 | 2025-01-31 | View Filing |
| 3 | 2025-01-31 | 2025-01-31 | View Filing |
| 4 | 2025-01-31 | 2025-01-31 | View Filing |
| 8-K | 2025-01-31 | 2025-01-31 | View Filing |
| 4 | 2025-01-29 | 2025-01-29 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Bull Bias | 9.26% | 0.99 | 39 | 0.25 | 0.12 | 11.74 |
| Williams PercentR Strategy | 9.11% | 2 | 22 | 0.42 | 0.17 | 11.58 |
| Super Trend Strategy | 8.78% | 1.06 | 39 | 0.72 | 0.36 | 3.85 |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxx | xxxx% | x | x | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxx | xxxxxx% | xxxx | xx | xxx | x | xxxx |
| xxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxx | xx | x | xxxx | xxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxx | x% | x | x | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxx | x | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxxx |